Merck & Co., Inc. (MRK) Stock Forecast & Price Target

$98.34 -1.72 (-1.72%)

(As of 05:45 PM ET)

Merck & Co., Inc. - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 21 Analyst Ratings

Sell
1

Hold
6

Buy
14

Based on 21 Wall Street analysts who have issued ratings for Merck & Co., Inc. in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 21 analysts, 1 has given a sell rating, 6 have given a hold rating, 11 have given a buy rating, and 3 have given a strong buy rating for MRK.

Consensus Price Target

$129.20
31.38% Upside

According to the 21 analysts' twelve-month price targets for Merck & Co., Inc., the average price target is $129.20. The highest price target for MRK is $155.00, while the lowest price target for MRK is $104.00. The average price target represents a forecasted upside of 31.38% from the current price of $98.34.

Get the Latest News and Ratings for MRK and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Merck & Co., Inc. and its competitors.

MRK Analyst Ratings Over Time

Type	Current Forecast 12/19/23 to 12/18/24	1 Month Ago 11/19/23 to 11/18/24	3 Months Ago 9/20/23 to 9/19/24	1 Year Ago 12/19/22 to 12/19/23
Strong Buy	3 Strong Buy rating(s)	2 Strong Buy rating(s)	3 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	11 Buy rating(s)	10 Buy rating(s)	9 Buy rating(s)	16 Buy rating(s)
Hold	6 Hold rating(s)	6 Hold rating(s)	2 Hold rating(s)	5 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$129.20	$130.86	$134.58	$125.14
Forecasted Upside	31.38% Upside	35.52% Upside	14.80% Upside	17.52% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

An extra $2 trillion a year for this industry? (Ad)

We're on the cusp of an energy revolution... I'm not talking about lithium batteries, renewable energies, or nuclear energy. This 'silent energy boom' is bigger than anything we've seen before.

Click here for the shocking truth

MRK Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

MRK Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Merck & Co., Inc. Stock vs. The Competition

Type	Merck & Co., Inc.	Medical Companies	S&P 500
Consensus Rating Score	2.76	2.81	2.51
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	28.84% Upside	28,685.97% Upside	11.91% Upside
News Sentiment Rating	Positive News See Recent MRK News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
12/10/2024	Bank of America 3 of 5 stars		Reiterated Rating	Buy	$121.00	+16.58%
12/4/2024	Hsbc Global Res 0 of 5 stars	R. Kumar Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
12/4/2024	HSBC 2 of 5 stars		Upgrade	Hold ➝ Buy	$130.00	+27.65%
11/15/2024	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	T. Anderson Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Peer Perform
11/11/2024	Daiwa America Subscribe to MarketBeat All Access for the recommendation accuracy rating	N. Nakagiri Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
11/11/2024	Daiwa Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral
Get the Latest News and Ratings for MRK and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Merck & Co., Inc. and its competitors with MarketBeat's FREE daily newsletter.
11/7/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$132.00 ➝ $130.00	+28.29%
11/6/2024	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$137.00 ➝ $130.00	+28.14%
11/1/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Equal Weight ➝ Equal Weight	$125.00 ➝ $110.00	+7.78%
11/1/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$150.00 ➝ $136.00	+32.59%
11/1/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Equal Weight ➝ Equal Weight	$130.00 ➝ $123.00	+19.70%
10/25/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$140.00 ➝ $130.00	+24.24%
10/17/2024	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Breen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Perform	$115.00	+4.14%
10/9/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$142.00 ➝ $136.00	+23.32%
10/7/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$142.00 ➝ $140.00	+28.83%
10/3/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$155.00 ➝ $155.00	+39.53%
7/30/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	U. Raffat Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/5/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Hellweg Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/8/2024	Berenberg Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$140.00 ➝ $143.00	+11.73%
3/11/2024	Societe Generale Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Hold ➝ Sell	$104.00	-15.33%
1/4/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Market Perform ➝ Outperform	$125.00 ➝ $135.00	+17.63%
11/9/2023	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$115.00	+10.15%
4/16/2023	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral
4/10/2023	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Mara Goldstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy	$130.00	+15.44%
3/7/2023	Atlantic Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight	$122.00 ➝ $127.00	+14.14%
3/7/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$125.00 ➝ $126.00	+13.24%
3/6/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$125.00	+16.95%
2/23/2023	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight	$120.00 ➝ $125.00	+13.08%
2/3/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$120.00 ➝ $122.00	+17.92%
1/3/2023	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$108.00 ➝ $120.00	+8.16%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 09:21 PM ET.

Should I Buy Merck & Co., Inc. Stock? MRK Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, December 15, 2024. Please send any questions or comments about these Merck & Co., Inc. pros and cons to contact@marketbeat.com.

Merck & Co., Inc.
Bull Case

Here are some ways that investors could benefit from investing in Merck:

Merck's stock price recently reached $102.00, indicating a stable market presence and potential for growth.
Institutional investors hold a significant 76.07% of Merck's stock, reflecting strong confidence in the company's future performance.
Merck has shown resilience with a market capitalization of approximately $258.02 billion, suggesting robust financial health and stability.
The company has a low debt-to-equity ratio of 0.79, indicating a manageable level of debt compared to its equity, which can be attractive to risk-averse investors.
Recent increases in holdings by major institutional investors, such as Franklin Resources Inc. and State Street Corp, signal positive sentiment and potential for future stock appreciation.

Merck & Co., Inc.
Bear Case

Investors should be bearish about investing in Merck for these reasons:

Merck's stock has experienced a 12-month high of $134.63, which may indicate that it is currently overvalued compared to its historical performance.
The company's 200-day moving average is $115.15, suggesting that the stock is trading below this average, which could be a sign of weakness.
Despite recent gains, the stock's price-to-earnings (P/E) ratio of 21.28 may be considered high, indicating that investors are paying a premium for earnings, which could limit future upside.
Market volatility and economic uncertainties could impact Merck's performance, making it a riskier investment in the current climate.
Recent fluctuations in stock price and trading volume may suggest instability, which could deter conservative investors looking for steady returns.

MRK Forecast - Frequently Asked Questions

: According to the research reports of 21 Wall Street equities research analysts, the average twelve-month stock price forecast for Merck & Co., Inc. is $129.20, with a high forecast of $155.00 and a low forecast of $104.00.
: 21 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Merck & Co., Inc. in the last year. There is currently 1 sell rating, 6 hold ratings, 11 buy ratings and 3 strong buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" MRK shares.
: According to analysts, Merck & Co., Inc.'s stock has a predicted upside of 31.38% based on their 12-month stock forecasts.
: Over the previous 90 days, Merck & Co., Inc.'s stock had 2 upgrades and 2 downgrades by analysts.
: Merck & Co., Inc. has been rated by research analysts at Bank of America, Barclays, BMO Capital Markets, Cantor Fitzgerald, Citigroup, Daiwa America, Daiwa Capital Markets, Guggenheim, Hsbc Global Res, HSBC, Morgan Stanley, Sanford C. Bernstein, Truist Financial, UBS Group, Wells Fargo & Company, and Wolfe Research in the past 90 days.
: Analysts like Merck & Co., Inc. less than other "medical" companies. The consensus rating score for Merck & Co., Inc. is 2.76 while the average consensus rating score for "medical" companies is 2.81. Learn more on how MRK compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Why is Buffett going all in on this? (Ad)

Warren Buffett has increased his already massive stake in this sector by almost 30% in the past few months. Microsoft and Blackrock created a special fund worth $100 billion to boost this 'silent' bull market. Institutional investors have a combined $2.8 trillion in this sector. Despite its "bad rap", this industry stubbornly rakes in profits.

Click here to learn more >>>

This page (NYSE:MRK) was last updated on 12/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Merck & Co., Inc. (MRK) Stock Forecast & Price Target